Literature DB >> 15529756

High hydrostatic pressure inactivated human tumour cells preserve their immunogenicity.

A Korn1, B Frey, A Sheriff, U S Gaipl, S Franz, R Meyer-Pittroff, G Bluemelhuberh, M Herrmann.   

Abstract

High hydrostatic pressure (HHP) is an established method to inactivate biomolecules and microoganisms. It is routinely used for the sterilization of foodstuff. Recently, new applications as inactivation of microorganisms and tumour cells for bone transplants or for cancer vaccines have emerged. Characterization of the HHP-induced cellular responses are a prerequisite for its clinical use. To this end, we investigated the fate of human cells after HHP by cytofluorometry. We observed that the induction by HHP of cell death is time- and pressure-dependent. Surprisingly, an HHP-treatment of 100 MPa did not reduce viability at any time point. Pressures from 150 to 250 MPa-induced programmed cell death in most cells. However, survivors were observed in long term culture experiments under these conditions. Pressures above 300 MPa immediately induced cell death by necrosis and completely inactivated the cells. In contrast to inactivation by other necrosis inducing treatments like heat, freeze/thaw, or chemical agents, HHP avoids generation of Maillard products and disintegration and lysis of the cells. Instead HHP generates a gelatinised mixture of antigens captured in a distinct and robust particle and maintains their humoral immunogenicity. The high viscosity of the internal matrix of a pressurised cell is reflected by the slow penetration of the low molecular compound propidium iodide and limits the bleeding of antigen before uptake by antigen presenting cells. Taken together, HHP is an alternative method for the inactivation of mammalian cells in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529756

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  6 in total

Review 1.  Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Authors:  Irena Adkins; Jitka Fucikova; Abhishek D Garg; Patrizia Agostinis; Radek Špíšek
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

2.  Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines.

Authors:  Kai Liu; Shuai Yan; Zhanchuan Ma; Bin Liu
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

3.  Research and application of hydrostatic high pressure in tumor vaccines (Review).

Authors:  Shuai Yan; Kai Liu; Lin Mu; Jianfeng Liu; Wan Tang; Bin Liu
Journal:  Oncol Rep       Date:  2021-03-24       Impact factor: 3.906

4.  Selected anti-tumor vaccines merit a place in multimodal tumor therapies.

Authors:  Eva-Maria Weiss; Roland Wunderlich; Nina Ebel; Yvonne Rubner; Eberhard Schlücker; Roland Meyer-Pittroff; Oliver J Ott; Rainer Fietkau; Udo S Gaipl; Benjamin Frey
Journal:  Front Oncol       Date:  2012-10-09       Impact factor: 6.244

Review 5.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

6.  High Hydrostatic Pressure Therapy Annihilates Squamous Cell Carcinoma in a Murine Model.

Authors:  Toshihito Mitsui; Naoki Morimoto; Atsushi Mahara; Sharon Claudia Notodihardjo; Tien Minh Le; Maria Chiara Munisso; Natsuko Kakudo; Tetsuji Yamaoka; Kenji Kusumoto
Journal:  Biomed Res Int       Date:  2020-03-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.